Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Post-stroke Cognitive Impairment
Interventions
DRUG

Edaravone dexborneol sublingual tablet

Patients will receive one edaravone dexborneol sublingual tablet twice daily for 24 weeks

DRUG

Placebo

Patients will receive one placebo twice daily for 24 weeks

Trial Locations (21)

Unknown

RECRUITING

Taihe County People's Hospital, Fuyang

RECRUITING

Hefei First People's Hospital, Hefei

RECRUITING

The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei

RECRUITING

The Second People's Hospital of Hefei, Hefei

RECRUITING

Huangshan City People's Hospital, Huangshan City

RECRUITING

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

RECRUITING

Wuzhou Red Cross Hospital, Wuzhou

RECRUITING

The Second Hospital of Hebei Medical University, Shijiazhuang

RECRUITING

Zhumadian Central Hospital, Zhumadian

RECRUITING

The Second Affiliated Hospital of Nanchang University, Nanchang

RECRUITING

The First Hospital of Jilin University, Changchun

RECRUITING

Liaoning Health Industry Group Bensteel General Hospital, Benxi

RECRUITING

The First Hospital of Dalian Medical University, Dalian

RECRUITING

The First People's Hospital of Shenyang, Shenyang

RECRUITING

Affiliated Hospital of Jining Medical College, Jining

RECRUITING

Liaocheng People's Hospital, Liaocheng

RECRUITING

Tai'an Central Hospital, Taian

RECRUITING

Suining Central Hospital, Suining

RECRUITING

Dongyang People's Hospital, Dongyang

RECRUITING

The First People's Hospital of Huzhou, Huzhou

RECRUITING

Zhuji People's Hospital of Zhejiang Province, Zhuji

All Listed Sponsors
lead

Simcere Pharmaceutical Co., Ltd

OTHER